Outlook Therapeutics is a biopharmaceutical company that develops and commercializes ophthalmic formulations of bevacizumab for treating retinal diseases, primarily wet age-related macular degeneration (wet AMD). The company's lead product is an FDA- and European Commission-approved ophthalmic bevacizumab formulation designed to address the substantial global anti-VEGF retina market by offering a properly manufactured, regulated alternative to higher-cost branded therapies and off-label repackaged compounds. Outlook generates revenue through direct commercialization in key markets and distribution partnerships, with outsourced manufacturing and field support from strategic partners, positioning itself as an affordable solution for ophthalmologists, retinal specialists, and healthcare systems while maintaining competitive pricing above off-label alternatives.